ShuYu Civilian Pharmacy Corp. Ltd. (301017) Fair Value & Analysis
Healthcare · CN · Market cap 5.5B CNY (≈ $822M) · ISIN CNE100004LT4
What is ShuYu Civilian Pharmacy Corp. Ltd. really worth?
A solid business, but trading 123% above our fair value of ¥5.91.
Strengths
Risks
For context
Fair value as of: Aug 27, 2026
From 24 valuation models · updated 9 days ago
Share price −5.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥7.39). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range ¥8.94 – ¥34.23 · fair‑value band ¥4.44 – ¥7.39 · the ¥13.15 price screens above the ¥5.91 fair value. Dashed = 300-day average. As of Aug 27, 2026.
Analysis
ShuYu Civilian Pharmacy Corp. Ltd. (301017) currently trades at ¥13.15, while our model-based Fair Value estimate is ¥5.91, implying the stock looks roughly 122.5% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥18.93 per share, and 11 of the 24 models we run sit above the ¥13.15 price. Bear case: the Asset-Based group reads lowest at ¥3.52, and 13 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, ShuYu Civilian Pharmacy Corp. Ltd. generated revenue of 10.6B CNY at a net margin of 0.9%. Revenue grew 9.4% year over year. It earns a return on equity of 4.7%. Net debt stands at 822M CNY. Fundamentals as of Aug 27, 2026
Our scenario range runs from ¥4.44 (bear case) to ¥7.39 (bull case); at ¥13.15, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −55%, 301017 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.1387 per share, which is 2.3 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (¥18.93) versus Asset-Based (¥3.52). Highest evidence: FCF DCF (77).
Notify me when 301017 reaches fair value
Put 301017 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
ShuYu Civilian Pharmacy Corp., Ltd. engages in the pharmaceutical retail chain business in China. The company is also involved in the pharmaceutical wholesale business. ShuYu Civilian Pharmacy Corp., Ltd. was founded in 1999 and is based in Jinan, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ShuYu Civilian Pharmacy Corp. Ltd. reported revenue of 10.3B CNY in FY2025 versus 5.3B CNY in FY2021, a compound +18.0%/yr. Reported net income was 114M CNY in FY2025, compounding −0.2%/yr from FY2021.
301017 screens 123% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 57 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.90 | ¥29.07 | +27% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.79 | ¥23.86 | +27% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | −71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | −21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | −19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | −38% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
| Luyan Pharma Co 002788 | ¥10.96 | ¥15.91 | +45% |
Compare ShuYu Civilian Pharmacy Corp. Ltd. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ShuYu Civilian Pharmacy Corp. Ltd. (301017) overvalued or undervalued?
What is the fair value of 301017?
What is the quality score of 301017?
What is the revenue of ShuYu Civilian Pharmacy Corp. Ltd. (301017)?
What is the net profit margin of 301017?
Does ShuYu Civilian Pharmacy Corp. Ltd. pay a dividend?
Watch ShuYu Civilian Pharmacy Corp. Ltd. in the live analysis
One click puts ShuYu Civilian Pharmacy Corp. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.